Notable Labs EPS - Earnings per Share 2013-2024 | NTBLQ
Notable Labs eps - earnings per share from 2013 to 2024. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| Notable Labs Annual EPS |
| 2023 |
$-3.41 |
| 2022 |
$-21.97 |
| 2021 |
$-15.73 |
| 2020 |
$-19.23 |
| 2019 |
$-18.88 |
| 2018 |
$-21.68 |
| 2017 |
$-12.94 |
| 2016 |
$-22.38 |
| 2015 |
$-25.53 |
| 2014 |
$-108.04 |
| 2013 |
$-553.15 |
| 2012 |
$-389.16 |
| Notable Labs Quarterly EPS |
| 2024-06-30 |
$-0.55 |
| 2024-03-31 |
$-0.42 |
| 2023-12-31 |
$7.07 |
| 2023-09-30 |
$-0.48 |
| 2023-06-30 |
$-3.54 |
| 2023-03-31 |
$-6.46 |
| 2022-12-31 |
$-9.10 |
| 2022-09-30 |
$-4.13 |
| 2022-06-30 |
$-4.20 |
| 2022-03-31 |
$-4.55 |
| 2021-12-31 |
$-4.20 |
| 2021-09-30 |
$-3.15 |
| 2021-06-30 |
$-4.20 |
| 2021-03-31 |
$-4.20 |
| 2020-12-31 |
$-4.90 |
| 2020-09-30 |
$-4.20 |
| 2020-06-30 |
$-4.90 |
| 2020-03-31 |
$-5.25 |
| 2019-12-31 |
$-5.25 |
| 2019-09-30 |
$-4.90 |
| 2019-06-30 |
$-4.55 |
| 2019-03-31 |
$-4.20 |
| 2018-12-31 |
$-3.50 |
| 2018-09-30 |
$-5.25 |
| 2018-06-30 |
$-4.55 |
| 2018-03-31 |
$-8.39 |
| 2017-12-31 |
$8.39 |
| 2017-09-30 |
$-8.39 |
| 2017-06-30 |
$-6.29 |
| 2017-03-31 |
$-6.64 |
| 2016-12-31 |
$-5.94 |
| 2016-09-30 |
$-4.20 |
| 2016-06-30 |
$-4.90 |
| 2016-03-31 |
$-7.34 |
| 2015-12-31 |
$-4.90 |
| 2015-09-30 |
$-10.14 |
| 2015-06-30 |
$-5.25 |
| 2015-03-31 |
$-5.25 |
| 2014-12-31 |
$251.05 |
| 2014-09-30 |
$-85.66 |
| 2014-06-30 |
$-112.94 |
| 2014-03-31 |
$-160.49 |
| 2013-12-31 |
$0.00 |
| 2013-09-30 |
$-145.46 |
| 2012-12-31 |
$0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.000B |
|
Notable Labs Ltd. is a clinical-stage platform therapeutics company developing predictive precision medicines for patients with cancer. Notable Labs Ltd., formerly known as Vascular Biogenics Ltd., is based in FOSTER CITY, Calif.
|
